Elicio TherapeuticsELTX
ELTX
About: Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
Employees: 26
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
0.35% less ownership
Funds ownership: 4.56% [Q3] → 4.21% (-0.35%) [Q4]
6% less funds holding
Funds holding: 18 [Q3] → 17 (-1) [Q4]
9% less capital invested
Capital invested by funds: $2.48M [Q3] → $2.25M (-$225K) [Q4]
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
110%
upside
Avg. target
$10
110%
upside
High target
$10
110%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Robert Burns 16% 1-year accuracy 28 / 172 met price target | 110%upside $10 | Buy Reiterated | 2 Apr 2025 |
Financial journalist opinion
Based on 5 articles about ELTX published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires
BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on April 15, 2025, Elicio granted inducement awards to Elicio's newly appointed Chief Strategy and Financial Officer, Preetam Shah, and two additional new employees, as an inducement material to Dr. Shah and such employees entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4), which grants were approved by the compensation committee of Elicio's board of directors in accordance with the Elicio 2024 Inducement Incentive Award Plan.
Positive
Zacks Investment Research
2 weeks ago
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?
Here is how Elicio Therapeutics (ELTX) and Inventiva S.A. Sponsored ADR (IVA) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
2 weeks ago
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know
Elicio Therapeutics (ELTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
2 weeks ago
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025
Neutral
GlobeNewsWire
3 weeks ago
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective as of the date hereof.
Positive
Seeking Alpha
2 months ago
Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data
Interim analysis from the phase 1/2 AMPLIFY-7P study, using ELI-002 for the treatment of KRAS mutant pancreatic cancer patients, is expected in the 1st half of 2025. The global pancreatic cancer market size is expected to reach $7.4 billion by 2032; It is said that approximately 88% of PDAC cases deal with the KRAS mutation. The company has already established a proposed phase 3 design with the FDA in a Type B meeting using ELI-002 for the treatment of patients with KRAS-mutant pancreatic cancer.
Neutral
GlobeNewsWire
2 months ago
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis
Neutral
GlobeNewsWire
4 months ago
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
Updated Phase 1 data include a 16.3-month median recurrence-free survival (“mRFS”) and 28.9-month median overall survival (“mOS”) from full study population
Neutral
GlobeNewsWire
5 months ago
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival (“DFS”) expected in H1 2025 Poster presentation at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting highlighted AMPLIFY-7P Phase 1a translational data, demonstrating durable T cell response and antigen spreading in patients with KRAS mutant tumors Elicio to provide updated relapse-free survival (“RFS”) and overall survival (“OS”) data from AMPLIFY-201 study in an oral presentation at the 2024 European Society for Medical Oncology (“ESMO”) Immuno-Oncology Congress Strengthened cash position, expected to support operations beyond the anticipated AMPLIFY-7P Phase 2 interim analysis
Neutral
GlobeNewsWire
5 months ago
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens
Charts implemented using Lightweight Charts™